Caolan has a successful executive career, in sales and business development, working globally in his day-to-day role at Mergon Group with world class OEMs in the automotive, industrial/renewables and medical device sectors including Tesla, Jaguar Land Rover, Abbott Diagnostics and Nexalus. He also has a distinguished record in working with leading industry groups and institutes including Irish Medtech Association, Irish Manufacturing Research (IMR), Dublin City University (DCU) and Advanced Materials and BioEngineering Research (AMBER).
Caolan Bushell, Non-Executive Chairman and VP Business Development at Mergon Group, commented:
“It is an immense privilege to chair a company like FMCI and I am very much looking forward to this new challenge. The world is seeing an upheaval in methods of transport and mobility not seen since humans transitioned from the horse to the automobile. FMCI has an unparalleled network of stakeholders and innovative collaborators with a huge desire to lead globally in areas like micro mobility, autonomous and connected driving, smart cities and vertical takeoff and landing aircraft. I believe FMCI can be an internationally recognized star in the future mobility space around which a local ecosystem can orbit and thrive.”
"I am very pleased that Caolan has agreed to become our Non-Executive Chairman. We have worked well together in the 3 years that Caolan has been on the board, and his new role will be pivotal as we continue to attract disruptors and innovators to Shannon and develop FMCI as a global leader in the development of future mobility. I also want to pay tribute to our outgoing chairman, Robert Shorten, who did a fantastic job chairing the company through its initial start-up phase and helping to guide it successfully through the tumultuous pandemic period”.